Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO ® (ivacaftor)
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicines to include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with KALYDECO® (ivacaftor) 150 mg, ahead of the medicine’s anticipated approval by the European Commission.
The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines — KALYDECO® (ivacaftor), ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), as well as the triple combination therapy if approved — and any future additional licensed indications for all of these medicines.
Reshma Kewalramani, M.D., Chief Executive Officer and President at Vertex, said, “I’m pleased that NHS England has recognized the value of KAFTRIO, and that Vertex and NHS England have been able to work quickly, collaboratively and flexibly to expand the existing reimbursement agreement to include the triple combination therapy in advance of the medicine being licenced. This will ensure that eligible patients in England will be among the first in Europe to benefit from access to this innovative medicine upon approval.”
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion for KAFTRIO®(ivacaftor/tezacaftor/elexacaftor) in a combination regimen with KALYDECO® (ivacaftor) 150 mg to treat people with cystic fibrosis (CF) ages 12 and older with one F508del mutation and one minimal function mutation (F/MF) or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
As part of the agreement with NHS England, Vertex has committed to submit ORKAMBI®, SYMKEVI® and KAFTRIO® to the National Institute for Health and Care Excellence (NICE) within an agreed upon timetable, allowing for a period of real-world data collection on the medicines.
Vertex will be working closely with the authorities in Northern Ireland, Wales and Scotland with the aim of securing an equivalent agreement in those countries as soon as possible.
Vertex’s CF medicines are reimbursed in more than 20 countries around the world including Australia, France, Germany, the Republic of Ireland, Italy, Switzerland, Spain, Denmark, the UK and the U.S.
About Cystic Fibrosis
Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.
About KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a Combination Regimen With KALYDECO® (ivacaftor)
KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with KALYDECO® (ivacaftor) is an investigational medicine developed for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. It recently received a CHMP positive opinion, with the EU license expected over the next few months.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit https://www.vrtx.com
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements by Dr. Kewalramani in this press release and statements regarding our expectations for the patient population that will be able to access Vertex’s medicines, the timing of such access, our commitment to submit ORKAMBI, SYMKEVI and KAFTRIO to NICE for a period of real-world data collection and our plans to secure additional agreements with other countries. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, risks related to obtaining approval for and commercializing our medicines in Europe, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
Vertex Pharmaceuticals Incorporated
International: +44 20 3204 5275
U.S.: +1 617-341-6992
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VentureIsrael Launches New Venture Capital Fund28.10.2020 01:08:00 CET | Press release
VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech start-ups. The fund investment strategy focuses on the companies with clear-cut technological advantages, an experienced management team and a flexible business strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006270/en/ VentureIsrael Early Stage Deep Tech Fund (Graphic: Business Wire) The fund first investments are a secure quantum communications system, an AI market research solution and a next-generation correspondent banking platform. VentureIsrael is managed by five partners – all investment experts with diverse backgrounds: Michael Harte - former COO of Santander UK and Barclays; Roman Gold, Gadi Isaev and Alexander Zarankin of JSCapital – the Israeli investment platform; and Igor Turkin of Investment Management Group. “The Israeli innovation industry is demonstrating phenomenal
State-of-the-art Photography Results and Immersive AR Experiences: Infineon and pmd Offer 3D-imager With Longest Range in the Market27.10.2020 21:22:00 CET | Press release
Gaming, virtual e-Commerce, 3D online education: Augmented Reality (AR) applications with three-dimensional depth sensors link the real with the digital world and are strongly demanded. Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) and pmdtechnologies developed a 3D depth sensor based on the Time of Flight (ToF)-technology which outperforms other solutions in the market and aims for target applications that offer a wider spectrum of innovative consumer usability. The 3D sensor market in smartphones for rear side cameras is expected to grow up to more than 500 million units per year until 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006197/en/ The new REAL3 ToF chip enables better photography results with a faster autofocus in low-light conditions or perfect night mode portraits based on picture segmentation. (Photo: Business Wire) “The latest 3D image sensor from Infineon and pmdtechnologies enables a new
IFF to Release Third Quarter 2020 Results November 927.10.2020 21:15:00 CET | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced that it will release its third quarter 2020 earnings results following the market close on Monday, November 9, 2020. The management team will host a live webcast on Tuesday, November 10, 2020 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, a
Panasonic: Verifiering av den hämmande effekten hos nanoe™ X, en teknik som nyttjar fördelarna med hydroxylradikaler, på det nya coronaviruset (SARS-CoV-2)27.10.2020 18:30:00 CET | Pressmeddelande
Panasonic tillkännagav idag, i samarbete med den globala kontraktforskningsorganisationen Texcell*1, att Texcell har verifierat den hämmande effekten hos nanoe™ X, en teknik som nyttjar fördelarna med hydroxylradikaler, på det det nya coronaviruset (SARS-CoV-2). nanoe™ X, en joniserare som genererar ”atomiserade vattenpartiklar av nanostorlek”, har utvecklas av Panasonic. Detta är en elektrostatisk atomiseringsteknik som samlar upp osynlig fukt i luften och tillför högspänning för att producera ”hydroxylradikaler i vattnet”. Den avgörande faktorn är att det förekommer hydroxylradikaler i nanoe™ X. Hydroxylradikalerna kännetecknas av att ha en hög oxidation och reaktivitet. Panasonic har bedrivit forskning på denna teknik sedan 1997 och har verifierat dess effektivitet på olika områden, inklusive hämning av vissa patogena mikroorganismer (bakterier, svampar och virus) och allergener, och att den bryter ned PM 2.5-komponenter som har negativa effekter på människokroppen*2. 2012 genomförd
VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART27.10.2020 17:40:00 CET | Press release
Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, presents the target market for its active substance TOTUM-070, for untreated mild to moderate LDL-hypercholesterolemia. The Phase II clinical study has been initiated and will begin as soon as authorizations are received from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP). TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols nor red yeast rice, developed to act on lipid metabolism in individuals with hypercholesterolemia. Once development is complete, this new Health Nutrition product will be positioned mainly for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 could be
Pulse Electronics Switches to Rimini Street Support for its SAP Applications27.10.2020 17:00:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Pulse Electronics, a leading components manufacturer for the automotive and telecommunications industries, has switched to Rimini Street support for its SAP ECC 6.0 and Business Objects software. With the savings achieved by switching support providers, Pulse was able to divert its liberated funding to invest in business intelligence (BI) capabilities including artificial intelligence (AI) technologies to enable growth and competitive advantage during a year when new spending may not have otherwise been possible. The company was also able to defer an expensive forced migration to S/4HANA, required to remain in full support with the vendor, and instead has taken complete control of its IT roadmap to support the businesses’ objectives versus the vendor’s dictated roa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom